Clinical Trials of COVID-19 Therapies Should Account for Diabetes and Hyperglycemia. (September 2021)

• Record Type: Journal Article
• Authors: Klonoff, David C.; Messler, Jordan; Valk, Timothy; Jagannathan, Ram; Pasquel, Francisco J.; Umpierrez, Guillermo E.
• Is Part Of: Journal of diabetes science and technology. Volume 15:Number 5(2021)
• Page Start: 1181
• Page End: 1187
• Publication Date: 2021-09
• Subjects: diabetes -- COVID-19 -- hospital -- clinical trial -- antiviral -- hyperglycemia; Diabetes -- Periodicals; Medical technology -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1177/19322968211013369
• Languages: English
• ISSNs: 1932-2968

Abstract

Complications of Coronavirus Disease 2019 (COVID-19) occur with increased frequency in people admitted to the hospital with diabetes or hyperglycemia. The increased risk for COVID-19 infections in the presence of these metabolic conditions is in part due to overlapping pathophysiologic features of COVID-19, diabetes, and glucose control. Various antiviral treatments are being tested in COVID-19 patients. We believe that in these trials, it will be useful to evaluate treatment effect differences in patients stratified according to whether they have diabetes or hyperglycemia. In this way, it will be possible to better facilitate development of antiviral treatments that are most specifically beneficial for the large subset of COVID-19 patients who have diabetes or hyperglycemia.